Scientific Impact Recognition Award: Molecular breast imaging: a review of the Mayo Clinic experience |
| |
Authors: | Hruska Carrie B Boughey Judy C Phillips Stephen W Rhodes Deborah J Wahner-Roedler Dietlind L Whaley Dana H Degnim Amy C O'Connor Michael K |
| |
Affiliation: | a Department of Nuclear Medicine, Mayo Clinic, Rochester, MN 55905, USA b Department of Surgery, Mayo Clinic, Rochester, MN, USA c Department of Radiology, Mayo Clinic, Rochester, MN, USA d Department of Internal Medicine, Mayo Clinic, 200 First St. SW, Rochester, MN, USA |
| |
Abstract: | BackgroundMolecular breast imaging (MBI) depicts functional uptake of targeted radiotracers in the breast using dedicated gamma cameras.MethodsMBI studies were performed under several institutional protocols evaluating the use of MBI in screening and diagnosis.ResultsBy using a single-head system, sensitivity for breast cancer detection was 85% (57 of 67) overall and 29% for tumors 5 mm or less in diameter. Sensitivity improved to 91% (117 of 128) overall and 69% for tumors 5 mm or less using a dual-head system. In 650 high-risk patients undergoing breast cancer screening, MBI detected 7 cancers, 5 of which were missed on mammography. In 24 of 149 (16%) breast cancer patients MBI detected additional disease not seen on mammography. The sensitivity of MBI was 88% (83 of 94) for invasive ductal carcinoma, 79% (23 of 29) for invasive lobular carcinoma, and 89% (25 of 28) for ductal carcinoma in situ.ConclusionsMBI can detect invasive ductal carcinoma, ductal carcinoma in situ, and invasive lobular carcinoma. It has a promising role in evaluating the extent of disease and multifocal disease in the breast for surgical treatment planning. |
| |
Keywords: | Molecular breast imaging Scintimammography Breast cancer Detection |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|